Jacob Schachter
Sheba Medical Center · 439 works · 31,750 citations · h-index 65
Top works
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over
- Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
- Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
- TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
- Early and late hematologic toxicity following CD19 CAR-T cells
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma
- Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma